Benzinga | Jan 31, 2022 09:18AM EST

Analyst Ratings For Intellia Therapeutics

Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish BearishTotal Ratings 1 2 1 0 0Last 30D 0 0 0 0 01M Ago 0 2 0 0 02M Ago 0 0 0 0 03M Ago 1 0 1 0 0

These 4 analysts have an average price target of $165.75 versus the current price of Intellia Therapeutics at $86.02, implying upside.

Below is a summary of how these 4 analysts rated Intellia Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This current average represents a 1.73% increase from the previous average price target of $168.67.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.